Overview

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antirheumatic Agents
Ixekizumab